Developing human laboratory models of smoking lapse behavior for medication screening.
about
Dopamine D4 receptors in psychostimulant addictionEffects of experimental negative affect manipulations on ad libitum smoking: a meta-analysisLarval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatmentLength of smoking deprivation moderates the effects of alcohol administration on urge to smokeFactors associated with use of breast cancer screening services by women aged >or= 40 years in Korea: the third Korea National Health and Nutrition Examination Survey 2005 (KNHANES III).Heightened vagal activity during high-calorie food presentation in obese compared with non-obese individuals--results of a pilot study.Weak ventral striatal responses to monetary outcomes predict an unwillingness to resist cigarette smoking.Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self-administration in young adults.The Impact of Job Stress on Smoking and Quitting: Evidence from the HRSNicotine and food deprivation decrease the ability to resist smokingLapse-induced surges in craving influence relapse in adult smokers: an experimental investigation.Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics.Posttraumatic stress symptoms and tobacco abstinence effects in a non-clinical sample: evaluating the mediating role of negative affect reduction smoking expectancies.Psychological symptoms, smoking lapse behavior, and the mediating effects of nicotine withdrawal symptoms: A laboratory study.Developing and validating a human laboratory model to screen medications for smoking cessation.Dependence and withdrawal-induced craving predict abstinence in an incentive-based model of smoking relapse.Modeling the effects of positive and negative mood on the ability to resist eating in obese and non-obese individualsStress decreases the ability to resist smoking and potentiates smoking intensity and rewardEffects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.Sex differences in stimulus expectancy and pharmacologic effects of a moderate dose of alcohol on smoking lapse risk in a laboratory analogue study.Behavioral economic analysis of cue-elicited craving for tobacco: a virtual reality studyPeroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence.Influence of affective manipulations on cigarette craving: a meta-analysis.Development of pharmacotherapies for drug addiction: a Rosetta stone approach.Sex differences in negative affect and lapse behavior during acute tobacco abstinence: a laboratory study.Publication trends in addiction research.Behavioral Economic Laboratory Research in Tobacco Regulatory Science.Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies.Second Generation Electronic Nicotine Delivery System Vape Pen Exposure Generalizes as a Smoking Cue.Predictors of smoking lapse in a human laboratory paradigm.Probing for Neuroadaptations to Unpredictable Stressors in Addiction: Translational Methods and Emerging Evidence.Reducing the harm of stress: medications to rescue the prefrontal cortex and overcome bad habits: the science of stress: focus on the brain, breaking bad habits, and chronic disease.Self-control depletion and nicotine deprivation as precipitants of smoking cessation failure: A human laboratory model.Toward a laboratory model for psychotherapeutic treatment screening: Implementation intentions and incentives for abstinence in an analog of smoking relapse.Happiness as a Buffer of the Association Between Dependence and Acute Tobacco Abstinence Effects in African American Smokers.Ovarian Hormones and Transdermal Nicotine Administration Independently and Synergistically Suppress Tobacco Withdrawal Symptoms and Smoking Reinstatement in the Human Laboratory.Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes.New dimensions in human laboratory models of addiction.Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study.
P2860
Q27026759-6F54DF38-F347-48D7-A4C0-770DAC9DEE34Q27315099-EFD41CCF-0C25-4A43-8628-1CF7C36CCDA5Q28541293-5BC9AD15-23B7-47A7-B46E-0590DB5B4738Q33555139-E51ECD1F-C9B8-4B8D-A4D0-B1C357B390C4Q33557708-56C4D2B2-FD20-4314-BD8F-CD0CB84313E1Q33651784-5039B919-1C67-451C-9CD7-6AE32F4A9C80Q34422430-C504EFC1-1B44-4487-823F-7BBA92AEEC11Q34870758-0738C081-46CC-4983-96AE-39B211346CD8Q34989821-3DCE1C34-2D56-4FD6-85D4-8C445BEA7F3DQ35010636-19BFEF98-26C8-41D4-9B08-6C12793CBA45Q35035989-BD9A9B1D-BCBF-4FEC-B32F-8FB06778B4B6Q35171207-A940B9A0-5725-46D6-AF26-FE832CA11057Q35282570-401764FA-3586-42B4-822C-9A3EE7933679Q35532088-8204C889-2C7E-4F08-AB1B-F442DF07A920Q35532120-A3DE62F1-D0A7-466E-A2A7-C88979072160Q36349950-40C3A1DA-F35A-4F53-B0C5-0E3D6F2A7F04Q36471933-A2B44B37-A32E-4987-8AFA-320738FA231EQ36786250-986B8973-35DE-48F1-8083-AB8BA0AE6C7FQ36798820-67D8424D-7A00-4742-950F-22002B588939Q36807528-9197878D-2901-460C-BE7F-4ED076A21DCFQ36942873-D1460017-5A25-45DF-BF27-94165C9DFFA3Q37024795-90F5E567-BCFC-4A51-B95E-D95D250638CAQ37304747-96CB9534-F1F9-47CD-8EF5-A4437D931F46Q37316011-08C6F1EA-4A91-445D-BAB9-43CA2B37618FQ37383571-9F3C343F-2F3B-4913-B71C-35A266485318Q37655387-4F02CCD5-22D4-4224-9F6C-A6978D08DE41Q37935107-3F5DFA68-EED9-4431-BE03-22685A3448AEQ38744516-C563229B-1036-4A22-AB90-A9AE55D24084Q38842262-56F32400-5C6C-4E16-B7C5-52B912764DA8Q39023725-969FE9F5-0184-4818-88DD-0F15B09B7EB2Q39255477-64539D18-233C-4FD5-979F-9FC038884A72Q39302789-F9ECAF63-04A6-4536-968A-82B4EC93C19CQ43012319-6A68ADAD-DB33-4AB3-A351-C9B60DCAB71BQ45055476-223E5D83-FC57-4742-AA14-6FC8900BE9F7Q45070428-AE28A385-16A2-4992-AB17-84AAE8FB2AEAQ46089842-98DF953E-A5F9-498F-BAE3-2418149EEB38Q47639854-80B7DAF6-CAE3-416E-8806-7F69B46ABE37Q48124586-2CB58BE2-AF6E-47C0-9C64-9372D124C273Q48304551-90B41A2A-7B98-4249-A5CE-1B1CE3044E69Q50042559-A8F2D3E8-B9DA-4860-BD3F-C55E27534F51
P2860
Developing human laboratory models of smoking lapse behavior for medication screening.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Developing human laboratory models of smoking lapse behavior for medication screening.
@en
Developing human laboratory models of smoking lapse behavior for medication screening.
@nl
type
label
Developing human laboratory models of smoking lapse behavior for medication screening.
@en
Developing human laboratory models of smoking lapse behavior for medication screening.
@nl
prefLabel
Developing human laboratory models of smoking lapse behavior for medication screening.
@en
Developing human laboratory models of smoking lapse behavior for medication screening.
@nl
P2860
P1433
P1476
Developing human laboratory models of smoking lapse behavior for medication screening.
@en
P2093
Sherry A McKee
P2860
P304
P356
10.1111/J.1369-1600.2008.00135.X
P577
2008-10-09T00:00:00Z